These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 33351661)
21. Medication Treatment of Adolescent Opioid Use Disorder in Primary Care. Carney BL; Hadland SE; Bagley SM Pediatr Rev; 2018 Jan; 39(1):43-45. PubMed ID: 29292291 [No Abstract] [Full Text] [Related]
22. Comparison between buprenorphine provider availability and opioid deaths among US counties. Jones CW; Christman Z; Smith CM; Safferman MR; Salzman M; Baston K; Haroz R J Subst Abuse Treat; 2018 Oct; 93():19-25. PubMed ID: 30126537 [TBL] [Abstract][Full Text] [Related]
23. A Telemedicine Buprenorphine Clinic to Serve New York City: Initial Evaluation of the NYC Public Hospital System's Initiative to Expand Treatment Access During the COVID-19 Pandemic. Tofighi B; McNeely J; Walzer D; Fansiwala K; Demner A; Chaudhury CS; Subudhi I; Schatz D; Reed T; Krawczyk N J Addict Med; 2022 Jan-Feb 01; 16(1):e40-e43. PubMed ID: 33560696 [TBL] [Abstract][Full Text] [Related]
24. Access to treatment for opioid use disorders: Medical student preparation. McCance-Katz EF; George P; Scott NA; Dollase R; Tunkel AR; McDonald J Am J Addict; 2017 Jun; 26(4):316-318. PubMed ID: 28394437 [TBL] [Abstract][Full Text] [Related]
25. Medicines for Patients After an Opioid Overdose. Ann Intern Med; 2018 Aug; 169(3):. PubMed ID: 29913484 [No Abstract] [Full Text] [Related]
26. Predictors of Medication Utilization for Opioid Use Disorder Among Medicaid-Insured HIV Patients in New York. Choi S; Yerneni R; Healy S; Goyal M; Neighbors CJ Am J Addict; 2020 Mar; 29(2):151-154. PubMed ID: 31951083 [TBL] [Abstract][Full Text] [Related]
27. Implementation of the hub and spoke model for opioid use disorders in California: Rationale, design and anticipated impact. Miele GM; Caton L; Freese TE; McGovern M; Darfler K; Antonini VP; Perez M; Rawson R J Subst Abuse Treat; 2020 Jan; 108():20-25. PubMed ID: 31399272 [TBL] [Abstract][Full Text] [Related]
28. Medication-Assisted Treatment of Opioid Use Disorder in Adolescents and Young Adults. Cottrill CB; Matson SC Adolesc Med State Art Rev; 2014 Aug; 25(2):251-65. PubMed ID: 27132312 [No Abstract] [Full Text] [Related]
29. Buprenorphine in the United States: Motives for abuse, misuse, and diversion. Chilcoat HD; Amick HR; Sherwood MR; Dunn KE J Subst Abuse Treat; 2019 Sep; 104():148-157. PubMed ID: 31370979 [TBL] [Abstract][Full Text] [Related]
30. Acute Care, Prescription Opioid Use, and Overdose Following Discontinuation of Long-Term Buprenorphine Treatment for Opioid Use Disorder. Williams AR; Samples H; Crystal S; Olfson M Am J Psychiatry; 2020 Feb; 177(2):117-124. PubMed ID: 31786933 [TBL] [Abstract][Full Text] [Related]
31. PRimary Care Opioid Use Disorders treatment (PROUD) trial protocol: a pragmatic, cluster-randomized implementation trial in primary care for opioid use disorder treatment. Campbell CI; Saxon AJ; Boudreau DM; Wartko PD; Bobb JF; Lee AK; Matthews AG; McCormack J; Liu DS; Addis M; Altschuler A; Samet JH; LaBelle CT; Arnsten J; Caldeiro RM; Borst DT; Stotts AL; Braciszewski JM; Szapocznik J; Bart G; Schwartz RP; McNeely J; Liebschutz JM; Tsui JI; Merrill JO; Glass JE; Lapham GT; Murphy SM; Weinstein ZM; Yarborough BJH; Bradley KA Addict Sci Clin Pract; 2021 Jan; 16(1):9. PubMed ID: 33517894 [TBL] [Abstract][Full Text] [Related]
33. Re-purposing anticoagulation clinics: expanding access to opioid agonist therapy in primary care settings. Lagisetty P; Heisler M; Bohnert A Addiction; 2017 Mar; 112(3):384-385. PubMed ID: 27550143 [No Abstract] [Full Text] [Related]
34. COVID-19: A catalyst for change in telehealth service delivery for opioid use disorder management. Mehtani NJ; Ristau JT; Snyder H; Surlyn C; Eveland J; Smith-Bernardin S; Knight KR Subst Abus; 2021; 42(2):205-212. PubMed ID: 33684331 [TBL] [Abstract][Full Text] [Related]
35. Get Waivered: A Resident-Driven Campaign to Address the Opioid Overdose Crisis. Martin A; Kunzler N; Nakagawa J; Lee B; Wakeman S; Weiner S; Raja AS Ann Emerg Med; 2019 Nov; 74(5):691-696. PubMed ID: 31272821 [No Abstract] [Full Text] [Related]
36. Expanding treatment for opioid use disorder in publicly funded primary care clinics: Exploratory evaluation of the NYC health + hospitals buprenorphine ECHO program. Tofighi B; Isaacs N; Byrnes-Enoch H; Lakew R; Lee JD; Berry C; Schatz D J Subst Abuse Treat; 2019 Nov; 106():1-3. PubMed ID: 31540604 [TBL] [Abstract][Full Text] [Related]
37. Feasibility of Implementing Shared Medical Appointments (SMAs) for Office-Based Opioid Treatment With Buprenorphine: A Pilot Study. Suzuki J; Zinser J; Klaiber B; Hannon M; Grassi H; Spinosa M; Ramirez A; Issa M; Chin Feman SP Subst Abus; 2015; 36(2):166-9. PubMed ID: 25738320 [TBL] [Abstract][Full Text] [Related]
38. Expanding access to buprenorphine treatment in rural areas with the use of telemedicine. Weintraub E; Greenblatt AD; Chang J; Himelhoch S; Welsh C Am J Addict; 2018 Dec; 27(8):612-617. PubMed ID: 30265425 [TBL] [Abstract][Full Text] [Related]
39. Geographic disparities in access to Medication for Opioid Use Disorder across US census tracts based on treatment utilization behavior. Mitchell P; Samsel S; Curtin KM; Price A; Turner D; Tramp R; Hudnall M; Parton J; Lewis D Soc Sci Med; 2022 Jun; 302():114992. PubMed ID: 35512612 [TBL] [Abstract][Full Text] [Related]